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OBJECTIVE — To determine whether glargine is noninferior to detemir regarding the per-
centage of patients reaching A1C 7% without symptomatic hypoglycemia 3.1 mmol/l.
RESEARCH DESIGN AND METHODS — In this 24-week trial, 973 insulin-naive type
2diabeticpatientsonstableoralglucose-loweringdrugswithA1C7.0–10.5%wererandomized
to glargine once daily or detemir twice daily. Insulin doses were systematically titrated.
RESULTS — 27.5 and 25.6% of patients reached the primary outcome with glargine and
detemir, respectively, demonstrating the noninferiority of glargine. Improvements in A1C were
1.46  1.09% for glargine and 1.54  1.11% for detemir (P  0.149), with similar
proportions of patients achieving A1C 7% (P  0.254) but more detemir-treated patients
reaching A1C 6.5% (P  0.017). Hypoglycemia risk was similar. Weight gain was higher for
glargine(difference:0.77kg,P0.001).Glarginedoseswerelowerthandetemirdoses:43.5
29.0 vs. 76.5  50.5 units/day (P  0.001).
CONCLUSIONS — In insulin-naive type 2 diabetic patients, glargine reached similar con-
trol as detemir, with more weight gain, but required signiﬁcantly lower doses.
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T
he “treat-to-target” clinical trials
havedemonstratedthattheaddition
of systematically titrated basal insu-
lin to existing oral therapy results in ade-
quate glycemic control in the majority of
patients with type 2 diabetes (1–3). The
basalinsulinanalogs,insulinglargineand
insulin detemir, achieve this with a re-
duced risk of hypoglycemia compared
with the conventional NPH insulin (1,2).
The aim of this study was to compare the
efﬁcacy,safety,andtheeffectonqualityof
lifeofonce-dailyglarginewithtwice-daily
detemir in insulin-naive patients with
type 2 diabetes inadequately controlled
on oral glucose-lowering drugs (OGLDs),
including metformin. The primary objec-
tive was to determine whether glargine
was noninferior to detemir regarding the
percentage of patients reaching A1C
7% without symptomatic hypoglyce-
mia with plasma glucose (PG) 3.1
mmol/l.
RESEARCH DESIGN AND
METHODS— The rationale for dos-
ing detemir twice daily and the study
methods we used have been detailed be-
fore(4).Inbrief,thismultinational,open-
label trial randomized insulin-naive type
2 diabetic subjects treated for 3 months
with stable OGLDs (including metformin
1 g/day) and with A1C of 7.0–10.5%,
to 24-week treatment with glargine in the
evening or detemir at breakfast and din-
ner. Glargine doses were increased every
2 days by 2 units until fasting PG reached
5.6 mmol/l, while the systematic titra-
tionofdetemirinvolvedthreestepstoob-
tain both fasting and predinner PG of
5.6 mmol/l (4).
The primary outcome was the per-
centage of patients reaching A1C 7%
without symptomatic hypoglycemia con-
ﬁrmed by PG 3.1 mmol/l. Secondary
outcomes included proportions of pa-
tients achieving A1C 7% and 6.5%,
hypoglycemia, weight, insulin doses, and
quality of life (5–8).
Noninferiority of glargine to detemir
was accepted if the lower limit of the two-
sided95%CIforthedifferenceinthepro-
portions of patients reaching the primary
outcome was 30% of the percentage of
detemir-treated patients achieving this
outcome (4).
RESULTS— Of 1,230 patients
screened, 973 were randomized, and 478
were treated with glargine and 486 with
detemir. More patients on glargine than
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and 89.9%, respectively, P  0.001). The
main reason for study discontinuation
was an adverse event: 7 patients on
glargine (1 event possibly related to study
drug) and 22 on detemir (20 possibly re-
lated) dropped out of the study due to
adverse events (P  0.005) (online Fig. A,
available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc09-2294). Online Table A shows the
population’s baseline characteristics. Of
865 patients using insulin secretagogs at
study entry, 42.4% stopped these at ran-
domization(43.5and41.4%intheglargine
and detemir groups, respectively).
In the glargine and detemir groups,
27.5 and 25.6% of patients, respectively,
reached A1C 7% without symptomatic
hypoglycemia with PG 3.1 mmol/l (dif-
ference: 1.85% [95% CI 3.78 to
7.48%]), demonstrating noninferiority of
glargine to detemir (noninferiority mar-
gin: 7.68%).
Secondary outcomes
Fig. 1A illustrates that the mean improve-
ments in A1C were similar: 1.46 
1.09% for glargine and 1.54  1.11%
for detemir (P  0.149). The proportions
of patients achieving A1C 7% were also
similar (44.1 and 47.8%, respectively,
P  0.254), but signiﬁcantly fewer
glargine- than detemir-treated patients
reached A1C 6.5% (16.5 and 22.7%,
respectively, P  0.017). The 8-point PG
proﬁles at baseline and end-of-study
showthatwhilethedecreaseinfastingPG
was signiﬁcantly greater for glargine (P 
0.001), detemir resulted in signiﬁcantly
larger reductions in PG before and after
lunch, before and after dinner, and at
bedtime (all P  0.001) (online Fig. B).
Risk of hypoglycemia was compara-
blebetweentreatmentswith30%ofpa-
tients experiencing symptomatic
hypoglycemia with PG 3.1 mmol/l in
either group (online Table B). Weight
gainwassigniﬁcantlyhigherwithglargine
versus detemir: 1.4  3.2 and 0.6  2.9
kg (P  0.001). Insulin doses, however,
were signiﬁcantly lower for glargine:
43.529.0versus76.550.5units/day
(P  0.001) (Fig. 1B). Quality of life im-
proved during the study with no differ-
ences between groups, except for a
discrepancy in treatment satisfaction in
favor of glargine (online Table C).
CONCLUSIONS — This “treat-to-
target” comparison between glargine and
detemir in insulin-naive patients with
type 2 diabetes demonstrated that
glargine and detemir result in similar im-
provementsinA1Candsimilarriskofhy-
poglycemia. In addition, our study
conﬁrms the higher weight gain, lower
daily insulin doses, and fewer drop-outs
(because of adverse events) for glargine
versus detemir, found in the previous
comparison of the two basal analogues in
this patient group (3). Finally, our ﬁnd-
ings suggest that initiating glargine or de-
temir in patients not achieving adequate
control on OGLDs positively affects qual-
ity of life.
Our study indicates that higher det-
emir doses may be needed to obtain the
same level of glycemic control as with
other basal insulins. This difference has
been attributed to the twice-daily dosing
ofdetemir(9),butNPHdosedtwice-daily
doesnotleadtodoseescalation(1).More-
over, trial data suggest that, although in-
sulin doses are indeed higher in patients
using detemir twice- versus once-daily,
once-daily detemir doses are still higher
than once-daily NPH and glargine doses
(3,10,11). At present there is no clear ex-
planation for the increased dose require-
ments for detemir (12).
Alimitationofourstudywasitsopen-
label design. This design was necessary,
however, as detemir was dosed twice-
Figure 1—A1C levels (A) and daily insulin doses (B) during the 24-week treatment period.
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fore dinner. As explained elsewhere (4), we
deliberately chose to dose detemir twice-
daily.Trialdataavailableatthetimeofthe
current study’s design suggested that
twice-dailydetemirreachedsuperiorA1C
compared with once-daily dosing (1,13).
The difference in dosing schedule for the
two insulins does, however, affect the in-
terpretation of some of our ﬁndings. Ad-
vantages of glargine over detemir, such as
the greater increase in treatment satisfac-
tion, may be explained by its once-daily
dosing and less complex titration. Also,
since the design of our study, the current
recommendation has become to initiate
detemir once-daily (based on a more re-
cent once-daily detemir versus NPH trial
showing noninferior A1C reductions for
detemir (11). Thus, with advancing
knowledge, it is now clear that another
“treat-to-target” trial comparing both
basal analogues using an identical, once-
daily dosing regimen is desirable.
In conclusion, we demonstrated
that in insulin-naive patients with type
2 diabetes glargine once-daily is nonin-
ferior to detemir twice-daily regarding
the percentage of patients reaching tar-
get A1C without hypoglycemia. Det-
emir-treated patients had less weight
gain and more often achieved A1C
6.5%, but the drop-out rate and daily
insulin doses were lower in the glargine
group.
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